Through a genome-wide forward CRISPR/Cas9 screen in interleukin-3 (IL3)-dependent Ba/F3 cells, we identified osteoclastogenesis-associated transmembrane protein 1 (OSTM1) as a previously unrecognized tumor suppressor. Analysis of patient datasets revealed that OSTM1 is frequently deleted or downregulated in human B-cell malignancies (BCM). In mice, Cd19-Cre-driven B cell–specific monoallelic or biallelic deletion of Ostm1 cooperated with Cdkn2a loss to drive lymphomagenesis with near-complete penetrance. Mechanistically, OSTM1 directly interacts with phosphodiesterase 3B (PDE3B) and promotes its proteasomal degradation. Because PDE3B hydrolyzes cyclic AMP (cAMP), loss of OSTM1 stabilizes PDE3B, leading to suppression of tumor-suppressive cAMP-dependent PKA/CREB signaling and promotion of oncogenic transformation. Consistent with this mechanism, PDE3B is frequently amplified or upregulated in BCM, and expression of CREB/CREBBP transcriptional targets correlates positively with OSTM1 expression but inversely with PDE3B across BCM cohorts. Importantly, silencing Pde3b reverses oncogenic transformation driven by Ostm1 loss. Together, these findings establish OSTM1 as a tumor suppressor and uncover an OSTM1/PDE3B/cAMP signaling axis that restrains B-cell lymphomagenesis and may represent a therapeutically actionable vulnerability.
Muhammad Usama Tariq, Namratha Sheshadri, Jianliang Shen, Jaeyong Jung, Rongrong Li, Hassan Sajjad, Mark C. Koch, Kevin Lu, Junrong Yan, Barbara Rosati, Giuseppe Caso, Brinda Vallat, Stephen K. Burley, Jun Wang, Christina Glytsou, Yi Sun, Tong Liu, Hong Li, Suzie Chen, Jiekun Yang, Zhiyuan Shen, Richard Z. Lin, Christian S. Hinrichs, Francesco Bertoni, Y. Lynn Wang, Jean Vacher, Ping Xie, Wei-Xing Zong
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.